About

This content provides supplementary information for the Tarceva (erlotinib) Dose Calculator. It outlines the key factors the calculator uses to determine dosing recommendations according to the FDA-approved prescribing information. This guide is intended for educational purposes for healthcare professionals and should not replace clinical judgment.

Outputs

The calculator provides the following key outputs based on the patient’s clinical parameters:

• Recommended Daily Dose: The final calculated oral dose in milligrams (mg) to be taken once daily.
• Dosing Rationale: A step-by-step summary showing how the base dose was adjusted based on factors like indication, smoking status, and concomitant medications.
• Administration Notes: Important instructions, such as administering the medication on an empty stomach.
• Clinical Warnings: Alerts for specific situations, such as use in patients with severe hepatic impairment or those taking interacting medications.

How to Use

To use the calculator, a clinician enters the following patient-specific information:

• Patient Indication: Select either Non-Small Cell Lung Cancer (NSCLC) or Pancreatic Cancer, as the base dose differs.
• Smoking Status: Indicate if the patient is a current cigarette smoker. Smoking induces CYP1A2 and increases erlotinib clearance, often requiring a higher dose.
• Concomitant Medications: Specify if the patient is taking strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin), which significantly alter erlotinib metabolism.
• Hepatic Function: (Optional) Note the patient’s hepatic status, particularly if severe impairment is present, as this requires cautious use and monitoring.

Dosing Overview

The standard dosing for Tarceva (erlotinib) varies by indication and is adjusted based on specific patient factors.

• NSCLC: The recommended dose is 150 mg orally once daily.
• Pancreatic Cancer: The recommended dose is 100 mg orally once daily, taken in combination with gemcitabine.
• Dose Reduction for Toxicity: For patients who develop intolerable toxicities, the dose can be reduced in 50 mg decrements.
• Administration: Tarceva should be taken on an empty stomach — at least one hour before or two hours after the ingestion of food.

Switching

This calculator is designed specifically for calculating erlotinib doses. It should not be used for determining equivalent doses when switching to or from other tyrosine kinase inhibitors (TKIs). Any switch in therapy should be guided by a qualified oncologist and based on the specific prescribing information for the new agent.

Missed Dose

If a patient misses a dose of Tarceva, they should not take the missed dose if it is close to the time of the next scheduled dose. The patient should skip the missed dose and take the next dose at the regularly scheduled time. Patients should be advised not to take two doses at the same time to make up for a missed one.

Safety Alerts

Clinicians should be aware of several key safety considerations when prescribing erlotinib:

• Interstitial Lung Disease (ILD): Severe, life-threatening, and fatal ILD-like events can occur. Withhold Tarceva for acute onset of unexplained pulmonary symptoms.
• Hepatotoxicity: Fatal hepatic failure and hepatorenal syndrome have been reported. Monitor periodic liver function tests.
• Gastrointestinal Perforation: A risk, particularly in patients receiving concomitant anti-angiogenic agents, corticosteroids, or NSAIDs.
• Bullous and Exfoliative Skin Disorders: Stevens-Johnson syndrome/toxic epidermal necrolysis cases have been reported.

Frequently Asked Questions (FAQ)

Why is the dose different for NSCLC and Pancreatic Cancer?
The approved doses (150 mg for NSCLC, 100 mg for Pancreatic Cancer) were established in separate clinical trials that demonstrated efficacy and safety for each specific indication at those levels.

How does smoking affect the Tarceva dose?
Cigarette smoking induces drug-metabolizing enzymes (primarily CYP1A2), which can decrease erlotinib plasma concentrations by over 50%. For NSCLC patients who smoke, the dose is typically increased to 300 mg daily.

What is a CYP3A4 inhibitor or inducer?
These are substances that affect the CYP3A4 enzyme, which is critical for metabolizing erlotinib. Inhibitors (like ketoconazole) slow metabolism, increasing drug levels and risk of toxicity. Inducers (like rifampin) speed up metabolism, reducing drug effectiveness.

The calculator recommended 75 mg. How do I administer that dose?
A 75 mg dose is typically a 50% reduction from the 150 mg base dose. Since a 75 mg tablet is not available, this may require a clinical decision to use a 50 mg or 100 mg tablet, or an alternative dosing schedule based on tolerability and clinical judgment.

What if a patient is on both an inhibitor and an inducer?
The calculator flags this as a conflict. The combined effect on drug levels is unpredictable and can be dangerous. The patient’s medication regimen should be re-evaluated by a clinician or pharmacist.

Why is severe hepatic impairment a special warning?
Erlotinib is metabolized by the liver. In severe impairment, the drug is not cleared properly, leading to significantly higher exposure and an increased risk of severe or fatal toxicity.

What does “take on an empty stomach” mean?
Food can significantly increase the absorption of erlotinib, leading to higher and more variable drug levels. It should be taken at least 1 hour before or 2 hours after a meal to ensure consistent absorption.

Can I use this calculator for dose adjustments due to side effects?
No. While the calculator notes that dose reductions can be made in 50 mg decrements, the decision to reduce a dose due to a specific toxicity (like rash or diarrhea) requires individualized clinical assessment by the prescribing healthcare provider.

References

• Tarceva (erlotinib) Full Prescribing Information. U.S. Food and Drug Administration. Revised: October 2016.
• Tarceva Official Website for Healthcare Professionals. Genentech, Inc.
• Pérez-Soler, R., et al. (2005). Determinants of Tumor Response and Survival With Erlotinib in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 23(33), 8567-8577. DOI: 10.1200/JCO.2005.02.8567
• Hamilton, G., & Gsur, A. (2012). Drug-drug interactions of erlotinib. Wiener medizinische Wochenschrift (1946), 162(19-20), 431–435. PMID: 23093259